FIG 2.

In vivo antileishmanial activity in model of early CL. The efficacies of DSHemsPC-AMB-Lip, AmBisome, and Fungizone in the susceptible L. major-infected BALB/c mouse model of early CL were determined. AMB formulations were i.v. administered on days 1, 2, 4, 7, 14, 21, and 28 after parasite injection. Values are the means ± standard errors of the means (weeks 0 to 3, n = 10; weeks 4 to 6, n = 7; weeks 7 to 9, n = 4). At weeks 2 and 3, there was a significant (*, P < 0.001) difference between the groups receiving DSHemsPC-AMB-Lip and AmBisome and the control groups (mice receiving 5% dextrose and empty liposome). At weeks 4 to 6, the difference between the DSHemsPC-AMB-Lip and control groups was significant (**, P ≤ 0.01). DSHemsPC-AMB showed greater activity than Fungizone (P ≤ 0.01).